FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort
Executive Summary
FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.
You may also be interested in...
GMPs On Tour: FDA Briefs EU, Japan To Avoid Trade Issues From New Rules
FDA is explaining its new good manufacturing practice regulations to regulatory officials in other countries to minimize disruptions in trade once they are implemented
GMPs On Tour: FDA Briefs EU, Japan To Avoid Trade Issues From New Rules
FDA is explaining its new good manufacturing practice regulations to regulatory officials in other countries to minimize disruptions in trade once they are implemented
FDA Office of Review Management
Center for Drug Evaluation & Research Deputy Director for Review Management Murray Lumpkin, MD, returns to his position Sept. 11 following a three month sabbatical at the European Medicines Evaluation Agency (1"The Pink Sheet" June 5, p. 8). Office of Drug Evaluation IV Director Dianne Murphy, MD, who served as acting deputy director of the review management branch, will retain her former titles, including Associate Director of Pediatrics